Publications by Grantees

The following list of publications describe research carried out with CIRM funding. Click on the publication title for a brief summary of the research and for more information about the CIRM grants that contributed to the research.

Title Year Journal
Sirtuins: critical regulators at the crossroads between cancer and aging. 2007 Oncogene
SOX9 is required for maintenance of the pancreatic progenitor cell pool. 2007 Proc Natl Acad Sci U S A
Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics. 2007 Proc Natl Acad Sci U S A
Switching of the core transcription machinery during myogenesis. 2007 Genes Dev
Systematic identification of cis-regulatory sequences active in mouse and human embryonic stem cells. 2007 PLoS Genet
Tgfb1 expressed in the Tgfb3 locus partially rescues the cleft palate phenotype of Tgfb3 null mutants. 2007 Dev Biol
The concentration of Nuf, a Rab11 effector, at the microtubule-organizing center is cell cycle regulated, dynein-dependent, and coincides with furrow formation. 2007 Mol Biol Cell
The prognostic role of a gene signature from tumorigenic breast-cancer cells. 2007 N Engl J Med
Channelrhodopsin-2 and optical control of excitable cells. 2006 Nat Methods
Drosophila neuroblast asymmetric cell division: recent advances and implications for stem cell biology. 2006 Neuron
Genetic Databases and Biobanks: Who Controls our Genetic Privacy? 2006 Santa Clara Computer and High Tech Law Journal
Identification of E2/E3 ubiquitinating enzymes and caspase activity regulating Drosophila sensory neuron dendrite pruning. 2006 Neuron
Postnatal deletion of Numb/Numblike reveals repair and remodeling capacity in the subventricular neurogenic niche. 2006 Cell
Potential of stem-cell-based therapies for heart disease. 2006 Nature
TRP channels and the regulation of vascular permeability: new insights from the lung microvasculature. 2006 Circ Res
Endothelial Cell Mechanotransduction in the Dynamic Vascular Environment Advanced Biosystems
Interim Results from a Phase I/II Clinical Gene Therapy Study for Newly Diagnosed Infants with X-Linked Severe Combined Immunodeficiency Using a Safety-Modified Lentiviral Vector and Targeted Reduced Exposure to Busulfan Blood
Lentiviral Gene Therapy with Low Dose Busulfan for Infants with X-Linked Severe Combined Immune Deficiency (XSCID) results in the Development of a Normal and Sustained Immune System: Interim Results of an ongoing Phase I/II Clinical Study ASGCT
1 … 59 60 61 62 63 64 65 66 67 68 69